Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0568

-11.3%

11:32 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	4/7/2014 9:56:01 AM
	Read Replies (1) of 13111

Study Says Skin Cancer Treatment Did Not Improve Survival Rates. Reuters (4/7) reported an experimental skin cancer treatment from Amgen Inc. failed to significantly improved survival rates in clinical trial patients. Still, the medicine met its primary goal to reduce the size of tumors, the article noted. The San Fernando Valley (CA) Business Journal (4/4) provided additional details, noting that “not only were survival rates disappointing, side effects included bacterial skin infection and fever.” According to the paper, Amgen “is hoping to get initial approval of the drug to treat skin cancer that has spread to other organs.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next